A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variants

Mostrar otras versiones (1)

Several vaccines have been introduced to combat the coronavirus infectious disease‐2019 (COVID‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Current SARS‐CoV‐2 vaccines include mRNA‐containing lipid nanoparticles or adenoviral vectors that encode the SARS‐CoV‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Linglei, Driedonks, Tom A.P., Jong, Wouter S.P., Dhakal, Santosh, Bart van den Berg van Saparoea, H., Sitaras, Ioannis, Zhou, Ruifeng, Caputo, Christopher, Littlefield, Kirsten, Lowman, Maggie, Chen, Mengfei, Lima, Gabriela, Gololobova, Olesia, Smith, Barbara, Mahairaki, Vasiliki, Riley Richardson, M., Mulka, Kathleen R., Lane, Andrew P., Klein, Sabra L., Pekosz, Andrew, Brayton, Cory, Mankowski, Joseph L., Luirink, Joen, Villano, Jason S., Witwer, Kenneth W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920961/
https://www.ncbi.nlm.nih.gov/pubmed/35289114
http://dx.doi.org/10.1002/jev2.12192
Mostrar todas las versiones(2)

Ejemplares similares